IGF2BP3 and hepatocellular carcinoma: In hepatocellular carcinoma mouse models, it modifies IGF2BP1’s configuration, reducing its efficacy.722 Another compound, “7773,” specifically disrupts the IGF2BP1-Kras mRNA interaction, effectively inhibiting IGF2BP1’s pro-oncogenic activity.723 Isoliquiritigenin is the only small molecule identified targeting IGF2BP3.724 Derived from the Chinese herb licorice, it downregulates IGF2BP3 expression, showing promise in treating non-small cell lung cancer.724